Departamento de Patologie et Pharmacologie, Instituto de Medicina y Biologia Experimental de Cuyo, Consejo Nacional de Investigación Cientifica y Tecnológica (IMBECU- CONICET), Mendoza 5500, Argentina.
Laboratorio de Farmacologia Experimental Básica y Traslacional, Departamento de Patologie et Pharmacologie, Área de Farmacologia, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza 5500, Argentina.
Curr Pharm Des. 2024;30(13):969-974. doi: 10.2174/0113816128289350240320063045.
In metabolic syndrome and diabetes, compromised mitochondrial function emerges as a critical driver of cardiovascular disease, fueling its development and persistence, culminating in cardiac remodeling and adverse events. In this context, angiotensin II - the main interlocutor of the renin-angiotensin-aldosterone system - promotes local and systemic oxidative inflammatory processes. To highlight, the low activity/expression of proteins called sirtuins negatively participates in these processes, allowing more significant oxidative imbalance, which impacts cellular and tissue responses, causing tissue damage, inflammation, and cardiac and vascular remodeling. The reduction in energy production of mitochondria has been widely described as a significant element in all types of metabolic disorders. Additionally, high sirtuin levels and AMPK signaling stimulate hypoxia- inducible factor 1 beta and promote ketonemia. Consequently, enhanced autophagy and mitophagy advance through cardiac cells, sweeping away debris and silencing the orchestra of oxidative stress and inflammation, ultimately protecting vulnerable tissue from damage. To highlight and of particular interest, SGLT2 inhibitors (SGLT2i) profoundly influence all these mechanisms. Randomized clinical trials have evidenced a compelling picture of SGLT2i emerging as game-changers, wielding their power to demonstrably improve cardiac function and slash the rates of cardiovascular and renal events. Furthermore, driven by recent evidence, SGLT2i emerge as cellular supermolecules, exerting their beneficial actions to increase mitochondrial efficiency, alleviate oxidative stress, and curb severe inflammation. Its actions strengthen tissues and create a resilient defense against disease. In conclusion, like a treasure chest brimming with untold riches, the influence of SGLT2i on mitochondrial function holds untold potential for cardiovascular health. Unlocking these secrets, like a map guiding adventurers to hidden riches, promises to pave the way for even more potent therapeutic strategies.
在代谢综合征和糖尿病中,受损的线粒体功能成为心血管疾病的关键驱动因素,推动其发展和持续存在,最终导致心脏重构和不良事件。在这种情况下,血管紧张素 II - 肾素-血管紧张素-醛固酮系统的主要对话者 - 促进局部和全身氧化炎症过程。值得强调的是,称为沉默调节蛋白的蛋白质的低活性/表达负参与这些过程,允许更显著的氧化失衡,这会影响细胞和组织反应,导致组织损伤、炎症和心脏和血管重构。线粒体能量产生的减少已被广泛描述为所有类型代谢紊乱的重要因素。此外,高沉默调节蛋白水平和 AMPK 信号刺激缺氧诱导因子 1β并促进酮血症。因此,通过心脏细胞增强自噬和线粒体自噬,清除碎片并沉默氧化应激和炎症的管弦乐,最终保护脆弱组织免受损伤。值得强调的是,特别有趣的是,SGLT2 抑制剂(SGLT2i)深刻地影响了所有这些机制。随机临床试验有力地证明了 SGLT2i 作为改变游戏规则的药物出现,其强大的作用可明显改善心脏功能,并降低心血管和肾脏事件的发生率。此外,受最近证据的驱动,SGLT2i 作为细胞超分子出现,发挥其有益作用以提高线粒体效率、减轻氧化应激和抑制严重炎症。其作用增强组织并为疾病提供强大的防御。总之,就像一个装满无数财富的宝库一样,SGLT2i 对线粒体功能的影响对心血管健康具有巨大的潜力。像一张引导冒险者寻找隐藏财富的地图一样,揭示这些秘密有望为更强大的治疗策略铺平道路。